DGAP-News: PAION AG REPORTS CONSOLIDATED FINANCIAL RESULTS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: PAION AG REPORTS CONSOLIDATED FINANCIAL RESULTS FOR THE FOR THE FIRST NINE MONTHS OF 2014

DGAP-News: PAION AG / Key word(s): 9-month figures PAION AG REPORTS CONSOLIDATED FINANCIAL RESULTS FOR THE FOR THE FIRST NINE MONTHS OF 2014 05.11.2014 / 07:30 --------------------------------------------------------------------- PAION AG REPORTS CONSOLIDATED FINANCIAL RESULTS FOR THE FOR THE FIRST NINE MONTHS OF 2014 - Positive Phase II results with Remimazolam in cardiac surgery - Licensing deals signed for Remimazolam in the MENA region and Canada - Proceeds of EUR 61.4 million from the capital increases for Phase III programmes with Remimazolam in the EU and the U.S. - PAION establishes U.S.-based subsidiary and engages experienced U.S. industry expert as CEO of PAION Inc - PAION gives update on preparations of Phase III programme with FDA and EMA, start in the U.S. planned for Q1 2015 - Conference call (in English) today at 4:00 pm CET (3:00 pm BT/10:00 am ET) Aachen (Germany), 05 November 2014 - Specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today reports its consolidated financial results according to International Financial Reporting Standards (IFRS) for the first nine months of 2014. In the first nine months of 2014, revenues amounted to EUR 1.9 million and thus were EUR 0.4 million higher than in the corresponding prior-year period. The revenues mainly relate to the licence agreements with R-Pharm (EUR 1.5 million), and Pendopharm (EUR 0.4 million). In the prior-year period, the revenues mainly resulted from a milestone payment from Yichang Humanwell and an option agreement with Hana Pharm. Research and development expenses rose from EUR 3.2 million in the prior-year period to EUR 6.9 million in the first nine months of 2014 due to increased development activities with Remimazolam. General administrative and selling expenses slightly increased from EUR 2.5 million to EUR 2.7 million compared to the prior-year period. In total, a net loss of EUR 6.3 million was incurred in the first nine months of 2014, thus exceeding the net loss of EUR 3.5 million in the prior-year period substantially but according to plan. Cash and cash equivalents increased by a total of EUR 49.6 million in the first nine months of 2014 mainly due to the capital increases conducted in the current fiscal year. As of 30 September 2014, PAION's cash and cash equivalents amounted to EUR 62.9 million. Thereby, PAION has sufficient funds to conduct the planned Phase III programmes with Remimazolam in the EU and the U.S., including the filing process, and to initiate premarketing and market access activities. Dr Wolfgang Söhngen, CEO of PAION AG commented: "In spite of the recent uncertainty with regard to the filing of Remimazolam in Japan by our partner Ono, we can look back at a very positive course of the year. In addition to the evaluation and release of the positive Phase II study data in cardiac surgery, our focus was primarily on the various capital measures, which will secure the funding for the development programme of Remimazolam and the planned approval process. In terms of our Phase III programmes, we have reached a final agreement with the FDA in the U.S. We expect the submission of study protocols still in November, so that the study can probably start in the first quarter of next year. We are also making good progress regarding Europe." Development and commercial activities In the first nine months of 2014, PAION focused on the development and partnering of Remimazolam. In February 2014, only five months after the start, patient recruitment of the Phase II clinical trial with the short-acting anaesthetic/sedative Remimazolam in the indication "General Anaesthesia" in patients undergoing cardiac surgery at the Heart Center Leipzig was completed and positive data were announced in May 2014. The safety profile was generally very good in all treatment groups. One of the key objectives of this trial was to assess the cardio stability during cardiac surgery with Remimazolam when compared to Propofol/Sevoflurane, both of which are known to may cause cardiac depression. In June 2014, PAION and R-Pharm, Russia, extended their licence agreement concerning the exclusive rights of development and commercialisation of Remimazolam to the MENA region, consisting of the Middle East and North Africa. Based on this extension, PAION received an upfront payment in the amount of EUR 1.5 million. Moreover, potential regulatory and commercial milestone payments of up to EUR 5.5 million and low double-digit royalties on net sales in the territory were agreed upon. After the completion of an exclusivity agreement with Pendopharm's European affiliate, Pharmascience International Ltd., in June 2014, the definitive licence agreement for the development and commercialisation of Remimazolam in the territory of Canada was signed in the beginning of July 2014. Based on this licence agreement, PAION is entitled to receive potential regulatory and commercial milestone payments of up to CAD 5.7 million (approximately EUR 4.0 million) and significant double-digit tiered royalties on net sales in Canada, starting at 15 %. A private placement in the volume of EUR 4 million at a subscription price of EUR 3.1463 followed. The 10 % premium to the share price of a total of EUR 0.4 million is disclosed as revenues. In September 2014, PAION entered into a licence agreement with Yichang Humanwell for the drug candidate M6G that had been written-off in 2011. Accordingly, Yichang Humanwell receives the exclusive licence for M6G and access to the data and know-how regarding the development, manufacturing and commercialisation of M6G in China. PAION will receive payments totalling EUR 1.6 million. Additional licence fees were not agreed. After the end of the reporting period, PAION's Japanese partner Ono informed the company in October 2014 that a decision on filing for Remimazolam in Japan is still open and is expected in November 2014. Due to continuing regulatory preparations for filing and the ongoing discussions concerning pharmacokinetic issues, filing is not expected in 2014. PAION's ongoing development programme in General Anaesthesia in Europe and Procedural Sedation in the U.S. are not affected. As part of the pre-marketing activities, PAION presented two scientific abstracts on Remimazolam at two important congresses in the U.S. PAION presented the Phase II trial results in anaesthesia at "The Anesthesiology 2014 Annual Meeting" (ASA) on 13 October 2014 in New Orleans, USA, and the colonoscopy Phase IIb trial results in procedural sedation at the "American College of Gastroenterology Annual Scientific Meeting" (ACG), 21 October 2014 in Philadelphia, USA. Remimazolam raised a lot of interest, and differentiation to the generic substances Midazolam and Propofol was confirmed by the specialists as a necessary innovation in the field of anaesthesia and procedural sedation in the context of a primary market research. In order to increase its presence in the North American market, PAION announced the foundation of its U.S. subsidiary PAION Inc. in October 2014. The new company, headquartered in New Jersey, has already started operational activities under the leadership of Greg Papaz. He will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The U.S. subsidiary will lead the positioning of Remimazolam in the United States, support the implementation of the U.S. Phase III programme for procedural sedation, and implement the strategic plan for market access and commercialisation of the sedative/anaesthetic Remimazolam in the U.S. Furthermore, key relationships with decision makers in the U.S. healthcare environment will be established. In the first nine months of 2014, PAION held further scientific meetings and interactions with the U.S. Food and Drug Administration (FDA) about Remimazolam for the U.S. lead indication "procedural sedation" and with the European Medicines Agency (EMA) for the EU lead indication "anaesthesia". At these meetings and interactions, the authorities commented the study protocols and other aspects of the development programme such as the production of the substance. As a result of a comprehensive coordination process and the feedback from the FDA, the Phase III study protocols are now being finalised and will presumably be submitted to the FDA in November 2014. With that, the study is expected to start in Q1 2015. Next steps are the opening of study centers and the treatment of the first patients. Conditional on successful results of this additional clinical testing, PAION expects filing for approval with the FDA earliest in the beginning of 2016. The coordination with the European Medicines Agency (EMA) for the EU lead indication "anaesthesia" has started as planned in the third quarter 2014. The discussions were constructive. The upcoming development programme until filing for market approval was discussed in the context of a scientific advice. Currently, further requests and considerations are being debated in the context of so-called "Clarification Letters" in order to come to a viable result. PAION expects the study to start in the first half of 2015, and filing for market approval for Remimazolam in the indication anaesthesia in the EU is possible at the earliest in the beginning of 2016, subject to successful study results. Capital measures During 2014, PAION conducted several capital increases. In total, these resulted in gross proceeds amounting to EUR 61.43 million. <pre> Type of capital Date Gross issue proceeds Issue Number of measure (EUR million) shares issued price (EUR) Private 22 July 4.00* 3.1463 1,271,334 placement 2014 Rights offering 9 July 2014 46.26 2.50 18,505,305 Private 17 February 3.17 2.4553 1,290,178 placement 2014 Private 22 January 3.00 2.4079 1,245,899 placement 2014 Rights offering 13 January 5.00 1.80 2,777,777 2014 Total 61.43 25,090,493 </pre> * EUR 0.4 million of the gross proceeds are disclosed as revenues in the context of the licence grant. Guidance 2014 Development and Commercialisation Activities PAION's major goals for the rest of 2014 are the completion of the preparation of the Phase III programmes with Remimazolam in the U.S. and the continuation of the preparations in Europe. The detailed talks with the authorities will be used to define the approval requirements. In addition, the main focus is on the production processes for Remimazolam, in particular the production of the test medication and the validation of the production in market scale. PAION expects the development activities of its cooperation partners for Remimazolam and GGF2 to continue. PAION expects ONO's decision on filing Remimazolam in Japan in November 2014. Due to ongoing regulatory preparations for filing and the not yet concluded interpretation of pharmacokinetic issues, filing is not expected to be initiated in 2014. Since PAION is evolving into a specialty pharmaceutical company with a focus on anaesthesia products, pre-marketing and market access activities will be implemented. This includes active participation in international congresses to position Remimazolam in the respective fields and to involve key opinion leaders. PAION seeks to retain certain marketing rights for Remimazolam for the European market in order to market Remimazolam in Europe directly or together with a partner. In case of a successful out-licensing of Remimazolam through a development cooperation, PAION could expect to receive substantial payments as upfront payments or as a contribution to development costs, development-related milestone payments as well as royalties from market approval onwards. In case of a pure marketing cooperation after registration, PAION expects to receive a comparably higher upfront payment and higher royalties. Financial Forecast In 2014, the revenues will presumably amount to EUR 3.5 million. These relate to the already recognised revenues from R-Pharm (EUR 1.5 million) and Pendopharm (EUR 0.4 million) as well as EUR 1.6 million expected revenue in the fourth quarter 2014 from the M6G licence agreement with Yichang Humanwell. Because of the investment in the development of Remimazolam, the research and development expenses will be higher than in the previous year and will amount to a high single-digit million range. Costs for selling and general administration will be higher than in the previous year especially due to pre-marketing activities, including the costs of PAION Inc. In total, a high single-digit to low double-digit million loss is expected for 2014. As of 30 September 2014, the PAION Group had cash and cash equivalents of EUR 62.9 million. With the cash and cash equivalents, PAION has sufficient funds to conduct the planned Phase III programmes with Remimazolam in the EU and the U.S., including the filing process, and to further initiate pre-marketing and market access activities. Moreover, PAION expects to receive further milestone payments from the existing cooperation agreements in case of successful development of Remimazolam or the filing for and receipt of market approval for Remimazolam in Japan and other regions. Future payments as well as cost reimbursements would strengthen the cash position but could also be completely or partially used to fund the development of the company. As of: 04 November 2014 ### Key consolidated financial figures, IFRS <pre> (all figures in EUR thousand unless Q1-Q3 Q1-Q3 noted otherwise) Q3 2014 Q3 2013 2014 2013 Revenues 366 300 1,887 1,523 Research and development expenses -2,631 -1,162 -6,929 -3,191 General administrative and selling expenses -823 -643 -2,705 -2,465 Profit/loss for the period -2,501 -1,311 -6,337 -3,501 Earnings per share in EUR for the period (basic) -0.05 -0.05 -0.18 -0.14 Earnings per share in EUR for the period (diluted) -0.05 -0.05 -0.18 -0.14 Q1-Q3 Q1-Q3 2014 2013 Cash flow from operating activities -8,094 -2,056 Cash flow from investing activities -19 0 Cash flow from financing activities 57,598 -7,163 Change in cash and cash equivalents 49,585 -9,344 Average number of employees in the Group 15 14 30-09- 31-12- 2014 2013 Intangible assets 3,525 3,494 Cash and cash equivalents 62,877 13,292 Equity 65,236 13,329 Non-current liabilities 19 28 Current liabilities 2,765 4,659 Total assets 68,020 18,016 </pre> The complete interim report of PAION for the period from 1 January to 30 September 2014 will be available as of 05 November 2014 on our corporate website at http://www.paion.com/en/berichte-2014. Conference call and webcast In addition to the publication of the results, the Management Board of PAION will host a public conference call (conducted in English) on 05 November 2014 at 4 p.m. CET (3 p.m. GMT, 8 a.m. EST) to present the financial results of Q3 2014, highlight the most important events and provide a pipeline and strategy update and financial outlook. To access the English call starting at 4 p.m., participants may dial from * Germany +49 (0) 69 7104 45598, * UK +44 (0) 20 3003 2666 and * US +1 212 999 6659 * Other countries: please use the UK number When prompted, you will be asked to give the password "PAION". The conference call will be supplemented by a webcast presentation which can be accessed during the call under the following link: www.meetingzone.com/presenter?partCEC=5422027. About PAION PAION AG is a listed specialty pharma company headquartered in Aachen, Germany, with a second site in Cambridge, UK. The company has a successful track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to extend its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products. The company's future marketing activities are to be based on Remimazolam. Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone +49 241 4453-152 E-mail r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------- 05.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 295036 05.11.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 0

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 9

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 0

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 31

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 91

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 157

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 46

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading

Top 5 Most Recently Viewed Articles

Bioretec's Innovative Annual Report Showcases New Progress

Updated Category News Views 188

Bioretec Ltd's Annual Report Overview Bioretec Ltd has recently published its annual report for 2024, offering insights into the company's growth and achievements over the past year. This report showcases the advancements made in biodegradable orthopedic implants, positioning the company at the forefront of innovative healthcare solutions. Company Highlights Bioretec...

Continue Reading
Market Overview: Asia Stocks See Fluctuations Amid Election Fears

Updated Category News Views 251

Market Dynamics in Asia: A Closer Look In recent trading sessions, Asian stocks demonstrated muted movements in response to an absence of compelling trading signals, while Japanese shares experienced a notable decline driven by impending democratic choices. Investors are particularly focused on the Japanese electoral scene, which is expected to significantly influence...

Continue Reading
TScan Therapeutics Secures $52.5 Million Loan to Support Growth

Updated Category News Views 113

TScan Therapeutics Secures $52.5 Million Loan from Silicon Valley Bank WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment, has announced an exciting milestone. The company has entered into a term loan facility with Silicon Valley Bank (SVB) that offers up to...

Continue Reading
Celebrating Four Years of SpaceX's Starlink Internet Service

Updated Category News Views 385

Four Years of Starlink Connectivity Four years ago, SpaceX, under the visionary leadership of Elon Musk, began its journey in satellite internet services by activating Starlink for its first paying customer. This significant milestone was established on a date that marks the beginning of a transformative era for internet connectivity. Impact of Starlink on Global Internet...

Continue Reading
AllenComm Receives Esteemed Recognition in eLearning Field

Updated Category News Views 167

AllenComm Earns Top Honor for eLearning Localization AllenComm, a prominent player in the realm of innovative learning experiences, has recently been recognized as one of the Top Content Providers for eLearning Localization by a well-regarded industry source. This accolade reflects the company's dedication to delivering high-quality, effective educational solutions that...

Continue Reading